Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in Cancer

Barzin Y. Nabet(Gene Therapy Laboratory), Andy J. Minn(Cancer Research Institute), Julia Tchou(University of Pennsylvania), Joseph Marcotrigiano(National Institute of Allergy and Infectious Diseases), Angela DeMichele(University of Pennsylvania), Jacob E. Shabason(Cancer Research Institute), Brian C. Kim(Cancer Research Institute), Joseph L. Benci(Cancer Research Institute), Yu Qiu(Cancer Research Institute), Taewon Yoon(Cancer Research Institute), Tony J. Wu(Cancer Research Institute)
Cell
July 1, 2017
10.1016/j.cell.2017.06.031
Cited by 448

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930
Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways
|Cell|2014|798
Integrating genomic features for non-invasive early lung cancer detection
|Nature|2020|689